Andrew S. Robertson is the North American Head of Regulatory Science & Policy at Sanofi, where he is responsible for developing, representing, and advocating for Sanofi Global and North American regulatory science priorities. His team represents Sanofi R&D concerning major legislative and regulatory initiatives, including the 21st Century Cures Act and user-fee reauthorization (FDARA), as well as emerging FDA approaches to drug development such as real-world evidence integration and patient-focused drug development.
Andrew has over 17 years’ experience in life science and regulatory policy. Prior to his work in the pharmaceutical industry, Andrew was a Science Policy Advisor at the U.S. Department of Health and Human Services’ Office of the Secretary and Office of Preparedness and Response, and a Faculty Research at the Wellcome Sanger Genomics Institute in Cambridge, UK.
Andrew holds a Ph.D. in molecular biochemistry from Cambridge University as a Gates Cambridge Scholar, and a JD from the University of California, Berkeley, School of Law. Andrew is admitted to the California Bar.